- 作者: Jing-Yi Lin, Yu-An Kung and Shin-Ru Shih
- 作者服務機構: 1. Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, Taiwan 2. Jing-Yi Lin and Yu-An Kung contributed equally, thus sharing first authorship. 3. Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan, Taiwan 4. Jing-Yi Lin and Yu-An Kung contributed equally, thus sharing first authorship. 5. Department of Medical Biotechnology and Laboratory Science, College of Medicine, Chang Gung University, Taoyuan, Taiwan 6. Department of Laboratory Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan 7. Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, and Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan, Taiwan
- 中文摘要:
- 英文摘要:
Enterovirus A71 (EV-A71) is an important emerging virus posing a threat to children under five years old. EV-A71 infection in infants or young children can cause hand-foot-and-mouth disease, herpangina, or severe neurological complications. However, there are still no effective antivirals for treatment of these infections. In this review, we summarize the antiviral compounds developed to date based on various targets of the EV-A71 life cycle. Moreover, development of a vaccine would be the most effective approach to prevent EV-A71 infection. Therefore, we also summarize the development and clinical progress of various candidate EV-A71 vaccines, including inactivated whole virus, recombinant VP1 protein, synthetic peptides, viral-like particles, and live attenuated vaccines. - 中文關鍵字:
- 英文關鍵字: Enterovirus A71, Antivirals, Vaccines